Almirall has announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the company’s aclidinium bromide/formoterol fumarate DPI for the treatment of COPD. Almirall will market the product as Duaklir Genuair and Brimica Genuair in Europe.
Almirall Chief Scientific Officer Thomas Eichholtz said, “We are very pleased with the CHMP positive recommendation for aclidinium bromide/formoterol fumarate. The committee’s positive opinion today marks a significant step forward in bringing this new treatment option to patients with COPD.”
AstraZeneca announced in July 2014 that it had acquired Almirall’s entire respiratory business. The acquisition is expected to be complete by the end of the year.
Read the Almirall press release.
